LIMITS-guided peptide design yields selective anti-tuberculosis host-defense peptides
The Penn State/University of Minnesota team used the Lead Informed Machine Interrogation of Therapeutic Sequences (LIMITS) workflow to train random-forest and neural-network predictors on approximately 100 host-defense peptides, using lead mutational scans and biophysical sequence features. Experimentally tested neural-network-designed MAD5.1 and MAD5.3 showed reported MICs of 5 μM against M. tuberculosis H37Rv, selectivity indices >16 against an eight-organism non-mycobacterial panel, and mammalian-cell toxicity indices >100. The study identifies peptide length as a potentially underappreciated activity determinant.
Technology: LIMITS (Lead Informed Machine Interrogation of Therapeutic Sequences), using random-forest and feed-forward neural-network predictors
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Experimentally tested neural-network-designed MAD5.1 and MAD5.3 showed reported MICs of 5 μM against M. tuberculosis H37Rv, selectivity indices >16 against an eight-organism non-mycobacterial panel, and mammalian-cell toxicity indices >100.
- Still unknown: This is preclinical in-vitro peptide evidence, not animal efficacy or clinical treatment. The paper reports that MAD5.3 did not produce a statistically significant reduction in H37Rv viability after seven days of culture despite its MIC and selectivity/toxicity metrics; do not generalize the headline activity to every candidate or assay. MAD2.2 was moderately hemolytic. The 5 μM H37Rv MIC and high indices apply to selected peptides and stated assay conditions.
- AI role: Lead-candidate mutational scanning informed feature selection and training on a limited ~100-peptide dataset; the models iteratively selected candidate anti-TB peptide sequences for synthesis and bacteriological testing. NN-predicted MAD5 sequences were assayed against virulent and avirulent M. tuberculosis strains and counter-screened against other bacteria and mammalian cells.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40310992/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 7 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.